Literature DB >> 9827972

Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.

S Carlens1, O Ringdén, M Remberger, B Lönnqvist, H Hägglund, S Klaesson, J Mattsson, B M Svahn, J Winiarski, P Ljungman, J Aschan.   

Abstract

Among 551 consecutive recipients of allogeneic bone marrow transplants, 451 survived more than 3 months and were evaluated for chronic graft-versus-host disease (GVHD). Most of the donors were HLA-identical siblings or parents (n = 334). Patients with HLA-mismatched donors (n = 30) and matched unrelated donors (MUD) (n = 87) were also included in the study. In the analysis of all patients, the 5-year cumulative incidence of chronic GVHD was 45%. We analysed 34 risk factors. High recipient age was the single most important risk factor (P < 0.001). Other significant risk factors in multivariate analysis were: acute GVHD grades I-IV (P < 0.001), immune female donor to male recipient (P = 0.006) and chronic myelogenous leukaemia (CML), compared with all other diagnoses (P = 0.014). The cumulative 5-year incidence of chronic GVHD, with no significant risk factors present, was 9%, 29% with one risk factor, 53% with two, 68% with three and 75% with all four risk factors present. In patients with HLA-identical sibling donors and GVHD prophylaxis consisting of a combination of methotrexate (MTX) and cyclosporin A (CsA) (n = 208), increasing recipient age (P < 0.001) and CML (P = 0.007), were found to be significant risk factors for chronic GVHD. Finally, a multivariate analysis in recipients of bone marrow from unrelated donors (n = 89) showed recipient age alone (P = 0.006) to be significantly associated with chronic GVHD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9827972     DOI: 10.1038/sj.bmt.1701423

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  39 in total

1.  Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care.

Authors:  Olle Ringdén; Mats Remberger; Johan Törlén; Sigrun Finnbogadottir; Britt-Marie Svahn; Behnam Sadeghi
Journal:  Int J Hematol       Date:  2021-02-05       Impact factor: 2.490

2.  Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants.

Authors:  Anita J Kumar; Soyoung Kim; Michael T Hemmer; Mukta Arora; Stephen R Spellman; Joseph A Pidala; Daniel R Couriel; Amin M Alousi; Mahmoud D Aljurf; Jean-Yves Cahn; Mitchell S Cairo; Corey S Cutler; Shatha Farhan; Usama Gergis; Gregory A Hale; Shahrukh K Hashmi; Yoshihiro Inamoto; Rammurti T Kamble; Mohamed A Kharfan-Dabaja; Margaret L MacMillan; David I Marks; Hideki Nakasone; Maxim Norkin; Muna Qayed; Olle Ringden; Harry C Schouten; Kirk R Schultz; Melhem M Solh; Takanori Teshima; Alvaro Urbano-Ispizua; Leo F Verdonck; Robert Peter Gale; Betty K Hamilton; Navneet S Majhail; Alison W Loren
Journal:  Blood Adv       Date:  2018-05-08

3.  Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion.

Authors:  James W Hart; Lisa H Shiue; Elizabeth J Shpall; Amin M Alousi
Journal:  Ther Adv Hematol       Date:  2013-10

4.  Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with thymoglobulin GVHD prophylaxis.

Authors:  A B M Lim; J Storek; A Beligaswatte; M Collins; M Tacey; T Williamson; K Mason; E Li; M A Chaudhry; J A Russell; A Daly; J Szer; I Lewis; D Ritchie
Journal:  Bone Marrow Transplant       Date:  2015-02-02       Impact factor: 5.483

5.  The H-Y Antigen in Embryonic Stem Cells Causes Rejection in Syngeneic Female Recipients.

Authors:  Xiaomeng Hu; Simon T Kueppers; Nigel G Kooreman; Alessia Gravina; Dong Wang; Grigol Tediashvili; Stephan Schlickeiser; Marco Frentsch; Christos Nikolaou; Andreas Thiel; Sivan Marcus; Sigrid Fuchs; Joachim Velden; Hermann Reichenspurner; Hans-Dieter Volk; Tobias Deuse; Sonja Schrepfer
Journal:  Stem Cells Dev       Date:  2020-08-25       Impact factor: 3.272

6.  Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease.

Authors:  Sharon R Hymes; Amin M Alousi; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2012-04       Impact factor: 11.527

7.  Gynecologic complication of chronic graft-versus-host disease: Vaginal obstruction.

Authors:  Junsik Park; Tae-Hee Kim; Hae-Hyeog Lee; Soo-Ho Chung; Daegeun Lee
Journal:  Obstet Gynecol Sci       Date:  2013-07-15

8.  Comparison of 2 preparative regimens for stem cell transplantation from HLA-matched sibling donors in patients with advanced myelodysplastic syndrome.

Authors:  Yoo-Jin Kim; Dong-Wook Kim; Seok Lee; Chang-Ki Min; Dong-Gun Lee; Soo-Mi Choi; Ki-Seong Eom; Hee-Je Kim; Jong-Wook Lee; Woo-Sung Min; Chun-Choo Kim
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

9.  Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands.

Authors:  Jeroen P Jansen; Amy K O'Sullivan; Elly Lugtenburg; Lambert F R Span; Jeroen J W M Janssen; Wiro B Stam
Journal:  Ann Hematol       Date:  2010-04-10       Impact factor: 3.673

Review 10.  Graft-versus-host disease.

Authors:  James L M Ferrara; John E Levine; Pavan Reddy; Ernst Holler
Journal:  Lancet       Date:  2009-03-11       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.